Security key
501575104
Kymera Therapeutics, Inc. - COMMON STOCK (KYMR)
CUSIP: 501575104
Q1 2026 13F Holders as of 31 Mar 2026
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 96,291,367
- Total 13F value
- $8,013,615,930
- Share change
- +6,195,470
- Put/Call ratio
- 105%
- SEC-reported price per share
- $83.29
- Number of holders
- 254
- Value change
- +$522,634,783
- Number of buys
- 128
- Number of sells
- 111
- Shares outstanding
- 81,496,373
Holder snapshot
7 signals
Show 1 more signal
Security identity
Who this page is about.
1 source field
Report period
Q1 2026
Institutions
254
Top holders
10
KYMR full security history
Ownership snapshot
Full 13F holder table
Previous quarter: Q4 2025
Kymera Therapeutics, Inc. SEC filings
Kymera Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 501575104
Recent filing periods:
Ownership snapshot
Top reported holders of KYMR - Kymera Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G
13F
3/4/5
Lead comparable stake: 14%
13D/G row: FMR LLC
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 14%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
FMR LLC
14%
BAKER BROS. ADVISORS LP
11%
BIOTECHNOLOGY VALUE FUND L P
8.5%
PRICE T ROWE ASSOCIATES INC /MD/
7.1%
T. Rowe Price Investment Manageme...
6.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
Company
|
14%
|
$1,034,158,808
11,681,450 shares
|
+$243,712,112 | 31 Mar 2026 |
| BAKER BROS. ADVISORS LP |
3/4/5
13D/G
13F
Director, 10%+ Owner · Company
|
11%
from 13D/G
|
$1,134,150,081
18,197,878 shares
mixed-class rows
|
+$230,183,852 | 11 Dec 2025 |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
BVF PARTNERS L P/IL
|
8.5%
|
$436,311,906
6,867,809 shares
|
$0 | 11 Dec 2025 |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
13D/G
Company · T. Rowe Price Associates, Inc.
|
7.1%
from 13D/G
|
$479,258,000
6,159,335 shares
|
— | 31 Dec 2025 |
| T. Rowe Price Investment Management, Inc. |
13D/G
13F
Company
|
6.7%
|
$483,396,552
5,460,257 shares
|
$0 | 31 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5.4%
from 13D/G
|
$389,368,651
5,004,095 shares
|
— | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2026
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
254
Shares
96,291,367
Rows available
254
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
253
Q1 2026 holders
254
Holder diff
1
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 value | Q1 2026 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend